Gordon Francis - Concepedia

Author

Gordon Francis

Novartis (Switzerland)

Also Known As

Francis Gordon, Gordon Francis

Publications

2.5K

Citations

H-Index

Concepts

All Affiliations

Novartis (Switzerland)Novartis (United States)Cleveland Clinic Amsterdam UMC Location Vrije Universiteit Amsterdam University Hospital of Basel

About

Gordon Francis is an author at Novartis (Switzerland) specializing in medicine, neuroimmunology, and neurology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	577
2	Neurology	4	4	489
3	Health Sciences	1	1	117
4	Public Health	1	1	10
5	Biostatistics	1	1	10

Gordon Francis

Publications

1.3K

Citations

H-Index

Page 1

	Year	Citations
Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study Bhupendra Khatri, Frederik Barkhof, Giancarlo Comi, The Lancet Neurology Amyotrophic Lateral SclerosisNeurobiology Of DiseaseDisease ProgressionNeurological DisorderMedicine	2011	215
Long-term effects of fingolimod in multiple sclerosis Ludwig Kappos, Paul O’Connor, Ernst‐Wilhelm Radue, Neurology	2015	187
Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis Jens Kühle, Giulio Disanto, Johannes Lorscheider, Neurology	2015	174
Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis Goeril Karlsson, Gordon Francis, Gideon Koren, Neurology	2014	154
Ophthalmic Evaluations in Clinical Studies of Fingolimod (FTY720) in Multiple Sclerosis Marco A. Zarbin, Lee M. Jampol, Rama D. Jager, Ophthalmology Ophthalmic EvaluationsOcular DiseaseOphthalmologyExperimental OphthalmologyMedicine	2013	147
Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis Ernst‐Wilhelm Radue, Frederik Barkhof, Ludwig Kappos, Neurology	2015	142
Fingolimod in relapsing multiple sclerosis: An integrated analysis of safety findings Ludwig Kappos, Jeffrey A. Cohen, William Collins, Multiple Sclerosis and Related Disorders Integrated AnalysisDisease ProgressionSafety FindingsMedicineNeurological Disorder	2014	117
Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS Jeffrey A. Cohen, Frederik Barkhof, Guillermo Izquierdo, Journal of Neurology Translational MedicineDisease MechanismClinical TranslationPatient SubgroupsMedicine	2013	88
The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing–Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis Frederik Barkhof, Remko de Jong, Nikolaos Sfikas, Multiple Sclerosis Journal	2014	45
Dealing with excess of zeros in the statistical analysis of magnetic resonance imaging lesion count in multiple sclerosis François Mercier, Peter Chin, Gordon Francis Pharmaceutical Statistics Neurological DisorderMagnetic ResonanceBrain LesionClinical TrialsBiostatistics	2012	10

Page 1